Product Code: BHL1358SA
“Global Cell and Gene Therapy Biomanufacturing Market to Reach $29.76 Billion by 2031.”
Overview
The global cell and gene therapy biomanufacturing market was valued at $12.31 billion in 2022 and is anticipated to reach $29.76 billion by 2031, witnessing a CAGR of 10.31% during the forecast period 2022-2031. The growth in the global cell and gene therapy biomanufacturing market is expected to be driven by the increased number of approved therapies and growing infrastructure requirements. In addition, expansion in target indications for cell and gene therapies creates a demand for large-scale biomanufacturing.
Market Lifecycle Stage
The global cell and gene therapy biomanufacturing market is in progressing phase. The cell and gene therapy market is developing rapidly due to its potential to target chronic and rare/orphan diseases that earlier had limited treatment options. Cell and gene therapies available in the market or in the pipeline are the result of years of pioneering research. Currently, there are more than 25 cell and gene therapies approved by the FDA in the last 10 years. These factors are expected to drive the demand for consumables, equipment, and software solutions required for manufacturing cell and gene therapy, thereby augmenting the growth of the cell and gene therapy biomanufacturing market.
Moreover, manufacturers began to produce application-specific cell and gene therapy equipment in recent years.
Impact
The field of medicine is transformed with the commercialization of cell and gene therapies. With the advent of time and introduction of new technologies, cell and gene therapy areas are flourishing. There is constant ongoing research for the development of novel cell and gene therapies. According to the American Society of Gene + Cell Therapy (ASGCT), as of February 2023, there are more than 2,000 clinical trials in the pipeline. The robust clinical pipeline for novel cell and gene entities is expected to create a lucrative opportunity for manufacturers and boost the growth of the cell and gene therapy biomanufacturing market.
Impact of COVID-19
In December 2019, Wuhan, a city in the Hubei region of China, was the site of the first detection of the COVID-19 outbreak. Following the classification of COVID-19 as novel pneumonia due to a cluster of unexplained pneumonia cases, efforts to pinpoint the culprit causing the outbreak and outline its genomic sequence got underway right once. The virus has already spread to every country on the globe, and researchers, governments, and business leaders are working to find answers to the crisis at a scale and speed that has never been seen. Testing for SARS-CoV-2 in the populace is one of the main steps that has been put into place globally, among many other measures used to stop the spread of the disease. The most crucial benefit of testing is that it offers evidence of illness, enabling individuals and those they have come into contact with to take the required precautions, including quarantining, to minimize community exposure.
The COVID-19 pandemic has substantially interrupted social, economic, and political activity around the world due to its unparalleled size and intensity. As a result, the cell and gene therapy (CGT) sector, which has historically struggled with tremendous complexity in the supply of materials, production, and logistical operations, has been disrupted by COVID-19.
The research, production, clinical development, and market introduction of CGTs for diseases unrelated to COVID-19 have all been significantly disrupted as a result of the COVID-19 pandemic. A lack of manufacturing material supplies, challenges with clinical studies, and delay in the creation of regulatory dossiers are all significant reasons. This has emphasized the significance of tackling the difficulties in CGTs' supply chain and production to increase resilience during the crisis.
To prevent CGTs' market access from being significantly disrupted, manufacturing resilience, digitalization, telemedicine, value-based pricing, and creative payment systems may be progressively tapped.
Market Segmentation:
Segmentation 1: by Product Type
- Consumables
- Equipment
- Software Solutions
Based on product, the consumables segment in the global cell and gene therapy biomanufacturing market dominated in FY2021. The equipment has a shelf life of five to seven years and software solutions also require a one-time investment with yearly maintenance costs. However, consumables are required more frequently and in large quantities for the production of cell and gene therapies.
Segmentation 2: by Usage
- Commercial Stage Manufacturing
- Research Stage Manufacturing
Based on usage, the global cell and gene therapy biomanufacturing market was dominated by the research stage manufacturing segment in FY2021.
Segmentation 3: by Application
- Upstream Processing
- Harvesting
- Downstream Processing
Based on application, the downstream processing segment accounted for the largest share of the global cell and gene therapy biomanufacturing in FY2021.
Segmentation 4: by End User
- Life Science Companies
- Contract Research Organizations (CROs)
- Contract Manufacturing Organizations (CMOs)
- Cell Banks
Based on end user, the global cell and gene therapy biomanufacturing market is dominated by the life sciences companies segment in FY2021.
Segmentation 5: by Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
In 2021, the North America cell and gene therapy biomanufacturing market dominated the global market with a 44.70% market share, and it is expected to hold its dominance throughout the forecast period 2022-2031. However, the Asia-Pacific (APAC) region, constituting several emerging economies, is expected to register the highest CAGR of 17.88% during the forecast period 2022-2031.
Recent Developments in the Global Cell and Gene Therapy Biomanufacturing Market
- In January 2023, Sartorius AG collaborated with Roosterbio Inc. to advance its downstream purification processes for the development of exosomes.
- In February 2022, Sartorius AG completed the acquisition of Novasep's chromatography division to complement its own product portfolio.
- In August 2022, Merck KGaA launched VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform to speed up the development of cell and gene therapies.
- In June 2022, Lonza Group AG and Adva Biotechnology Ltd. entered into a license agreement that provides the latter access to the former's core intellectual property enabling the expansion of automated bioreactors worldwide.
- In June 2022, Becton, Dickinson and Company launched FACSDiscover S8 Cell Sorter featuring CellView Image Technology.
- In January 2023, Bio-Techne Corporation launched RNAscope plus assay to advance its gene therapy development.
- In September 2021, Thermo Fisher Scientific Inc. launched the integrated Gibco AAV-MAX Helper Free AAV Production System for AAV vector production.
Demand - Drivers and Limitations
The following are the demand drivers for the global cell and gene therapy biomanufacturing market:
- Increasing Number of Approved Therapies and Growing Infrastructure Requirements Creating an Upsurge Demand for Cell and Gene Therapy Biomanufacturing Products
- Expansion in Target Indications for Cell and Gene Therapies Creating a Demand for Large-Scale Biomanufacturing
- Entry of New Market Participants in Cell and Gene Therapies Driving the Demand for Biomanufacturing Facilities and Equipment
- Increasing Investments and Fundings in Cell and Gene Therapy Fuelling the Growth of Cell and Gene Therapy Biomanufacturing
The market is expected to face some limitations due to the following challenges:
- High Set-Up Cost of Biomanufacturing Facilities
How can this report add value to an organization?
- Workflow/Innovation Strategy: The cell and gene therapy biomanufacturing market (by product type) has been segmented into consumables, equipment, and software solutions. Moreover, the study provides the reader with a detailed understanding of the different applications of cell and gene therapy biomanufacturing in upstream processing, harvesting, and downstream processing.
- Growth/Marketing Strategy: Cell and gene therapy biomanufacturing is being used for upstream processing, harvesting, downstream processing, and other applications. Various companies are providing consumables and equipment aid in the manufacturing of various cell and gene therapies, which is also the key strategy for market players to excel in the current cell and gene therapy biomanufacturing market.
- Competitive Strategy: Key players in the global cell and gene therapy biomanufacturing market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the global cell and gene therapy biomanufacturing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Companies Profiled:
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Bio-Techne Corporation
- Danaher Corporation
- Endress+Hauser Group Services AG (Analytik Jena GmbH)
- General Electric Company (GE Healthcare)
- Getinge AB
- Infors AG
|
- Lonza Group Ltd
- Merck KGaA
- Miltenyi Biotec B.V. & Co. KG
- PIERRE GUERIN
- Sartorius AG (Sartorius Stedim Biotech S.A.)
- Thermo Fisher Scientific Inc.
- WuXi AppTec
|
Table of Contents
1 Markets
- 1.1 Market Outlook
- 1.1.1 Product Definition
- 1.1.2 Inclusion and Exclusion Criteria
- 1.1.3 Key Findings
- 1.1.4 Assumptions and Limitations
- 1.1.5 Market Growth Scenarios
- 1.1.5.1.1 Realistic Growth Scenario
- 1.1.5.1.2 Optimistic Growth Scenario
- 1.1.5.1.3 Pessimistic Growth Scenario
- 1.2 Industry Outlook
- 1.2.1 Market Overview and Ecosystem
- 1.2.2 Key Trends
- 1.2.2.1 Biomanufacturing 4.0
- 1.2.2.2 Growing Single-Use Technology Market Penetration
- 1.2.2.3 Shift from Open Processing to Closed Processing for Cell and Gene Therapy Biomanufacturing
- 1.2.2.4 Leveraging Various Key Strategies to Diversify the Product Portfolio
- 1.2.3 Opportunity Assessment
- 1.2.4 Regulatory Framework
- 1.2.5 Product Benchmarking
- 1.2.5.1 Product Benchmarking (by Product Type)
- 1.2.5.2 Comparative Analysis (by Equipment)
- 1.2.6 Patent Analysis
- 1.2.6.1 Patent Analysis (by Year)
- 1.2.6.2 Patent Analysis (by Country)
- 1.2.6.3 Awaited Technologies
- 1.2.7 Business Model Analysis
- 1.2.8 Pipeline Products
- 1.2.9 Technology Adoption Matrix
- 1.2.10 Funding Scenario
- 1.2.11 Key Success Factors
- 1.3 Business Dynamics
- 1.3.1 Business Drivers
- 1.3.1.1 Increasing Number of Approved Therapies and Growing Infrastructure Requirements Creating an Upsurge Demand for Cell and Gene Therapy Biomanufacturing Products
- 1.3.1.2 Expansion in Target Indications for Cell and Gene Therapies Creating a Demand for Large-Scale Biomanufacturing
- 1.3.1.3 Entry of New Market Participants in Cell and Gene Therapies Driving the Demand for Biomanufacturing Facilities and Equipment
- 1.3.1.4 Increasing Investments and Fundings in Cell and Gene Therapy Fuelling the Growth of Cell and Gene Therapy Biomanufacturing
- 1.3.1.5 Impact Analysis
- 1.3.2 Business Restraints
- 1.3.2.1 High Set-Up Cost of Biomanufacturing Facilities
- 1.3.2.2 Impact Analysis
- 1.3.3 Business Opportunities
- 1.3.3.1 Integration of Automation into the Cell and Gene Therapy Biomanufacturing Workflow
- 1.3.3.2 Robust Clinical Pipeline Creating a Demand for Biomanufacturing Infrastructure
- 1.4 Impact of COVID-19 on the Cell and Gene Therapy Biomanufacturing Market
- 1.4.1 Recommendations to Manufacturers
- 1.5 Impact of Russo-Ukrainian War on Cell and Gene Therapy Biomanufacturing Market
2 Global Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 2.1 Overview
- 2.2 Opportunity Assessment
- 2.3 Consumables
- 2.3.1 Culture Supplements
- 2.3.1.1 Media
- 2.3.1.2 Serum
- 2.3.1.3 Macronutrients
- 2.3.2 Single-Use Liquids
- 2.3.3 Cell Culture Reagents
- 2.3.4 Cell Quantification Kits
- 2.4 Equipment
- 2.4.1 Bioreactors/Fermenters
- 2.4.1.1 Continuous Bioreactors
- 2.4.1.2 Single-Use Bioreactors
- 2.4.2 Mixing Systems
- 2.4.3 Cell Counters
- 2.4.4 Cell Sorters
- 2.4.5 Centrifuges
- 2.4.6 Incubators
- 2.4.7 Biosafety Cabinets
- 2.4.8 Freezers
- 2.4.9 PCR Systems
- 2.4.10 Transfection Systems
- 2.4.11 Storage Tanks
- 2.4.12 Others
- 2.5 Software Solutions
3 Global Cell and Gene Therapy Biomanufacturing Market (by Application)
- 3.1 Overview
- 3.2 Opportunity Assessment
- 3.3 Upstream Processing
- 3.3.1 Formulation and Hydration
- 3.3.2 Cell Culture Processing
- 3.4 Harvesting
- 3.5 Downstream Processing
- 3.5.1 Separation and Filtration
- 3.5.2 Fill and Finish Operations
4 Global Cell and Gene Therapy Biomanufacturing Market (by Usage)
- 4.1 Overview
- 4.2 Opportunity Assessment
- 4.3 Commercial Stage Manufacturing
- 4.4 Research Stage Manufacturing
5 Global Cell and Gene Therapy Biomanufacturing Market (by End User)
- 5.1 Overview
- 5.2 Opportunity Assessment
- 5.3 Life Sciences Companies
- 5.3.1 Equipment
- 5.3.2 Consumables
- 5.3.3 Software Solutions
- 5.4 Contract Research Organizations (CROs)
- 5.4.1 Equipment
- 5.4.2 Consumables
- 5.4.3 Software Solutions
- 5.5 Contract Manufacturing Organizations (CMOs)
- 5.5.1 Equipment
- 5.5.2 Consumables
- 5.5.3 Software Solutions
- 5.6 Cell Banks
- 5.6.1 Equipment
- 5.6.2 Consumables
- 5.6.3 Software Solutions
6 Global Cell and Gene Therapy Biomanufacturing Market (by Region)
- 6.1 North America
- 6.1.1 Key Findings and Opportunity Assessment
- 6.1.2 Market Dynamics
- 6.1.3 Sizing and Forecast Analysis
- 6.1.3.1 North America Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.1.3.2 North America Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.1.3.3 North America Cell and Gene Therapy Biomanufacturing Market (by Country)
- 6.1.3.3.1 U.S.
- 6.1.3.3.1.1 U.S. Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.1.3.3.1.2 U.S. Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.1.3.3.2 Canada
- 6.1.3.3.2.1 Canada Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.1.3.3.2.2 Canada Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.2 Europe
- 6.2.1 Key Findings and Opportunity Assessment
- 6.2.2 Market Dynamics
- 6.2.3 Sizing and Forecast Analysis
- 6.2.3.1 Europe Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.2.3.2 Europe Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.2.3.3 Europe Cell and Gene Therapy Biomanufacturing Market (by Country)
- 6.2.3.3.1 Germany
- 6.2.3.3.1.1 Germany Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.2.3.3.1.2 Germany Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.2.3.3.2 Italy
- 6.2.3.3.2.1 Italy Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.2.3.3.2.2 Italy Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.2.3.3.3 U.K.
- 6.2.3.3.3.1 U.K. Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.2.3.3.3.2 U.K. Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.2.3.3.4 Spain
- 6.2.3.3.4.1 Spain Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.2.3.3.4.2 Spain Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.2.3.3.5 France
- 6.2.3.3.5.1 France Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.2.3.3.5.2 France Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.2.3.3.6 Rest-of-Europe
- 6.2.3.3.6.1 Rest-of-Europe Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.2.3.3.6.2 Rest-of-Europe Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.3 Asia-Pacific
- 6.3.1 Key Findings and Opportunity Assessment
- 6.3.2 Market Dynamics
- 6.3.3 Sizing and Forecast Analysis
- 6.3.3.1 Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.3.3.2 Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.3.3.3 Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Country)
- 6.3.3.3.1 China
- 6.3.3.3.1.1 China Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.3.3.3.1.2 China Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.3.3.3.2 Japan
- 6.3.3.3.2.1 Japan Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.3.3.3.2.2 Japan Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.3.3.3.3 India
- 6.3.3.3.3.1 India Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.3.3.3.3.2 India Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.3.3.3.4 South Korea
- 6.3.3.3.4.1 South Korea Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.3.3.3.4.2 South Korea Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.3.3.3.5 Australia/New Zealand
- 6.3.3.3.5.1 Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.3.3.3.5.2 Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.3.3.3.6 Rest-of-Asia-Pacific
- 6.3.3.3.6.1 Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.3.3.3.6.2 Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.4 Latin America
- 6.4.1 Key Findings and Opportunity Assessment
- 6.4.2 Market Dynamics
- 6.4.3 Sizing and Forecast Analysis
- 6.4.3.1 Latin America Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.4.3.2 Latin America Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.4.3.3 Latin America Cell and Gene Therapy Biomanufacturing Market (by Country)
- 6.4.3.3.1 Argentina
- 6.4.3.3.1.1 Argentina Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.4.3.3.1.2 Argentina Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.4.3.3.2 Brazil
- 6.4.3.3.2.1 Brazil Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.4.3.3.2.2 Brazil Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.4.3.3.3 Mexico
- 6.4.3.3.3.1 Mexico Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.4.3.3.3.2 Mexico Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.4.3.3.4 Rest-of-Latin America
- 6.4.3.3.4.1 Rest-of-Latin America Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.4.3.3.4.2 Rest-of-Latin America Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.5 Middle East and Africa
- 6.5.1 Key Findings and Opportunity Assessment
- 6.5.2 Market Dynamics
- 6.5.3 Sizing and Forecast Analysis
- 6.5.3.1 Middle East and Africa Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.5.3.2 Middle East and Africa Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.5.3.3 Middle East and Africa Cell and Gene Therapy Biomanufacturing Market (by Country)
- 6.5.3.3.1 Kingdom of Saudi Arabia
- 6.5.3.3.1.1 Kingdom of Saudi Arabia Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.5.3.3.1.2 Kingdom of Saudi Arabia Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.5.3.3.2 U.A.E.
- 6.5.3.3.2.1 U.A.E. Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.5.3.3.2.2 U.A.E. Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.5.3.3.3 Israel
- 6.5.3.3.3.1 Israel Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.5.3.3.3.2 Israel Cell and Gene Therapy Biomanufacturing Market (by End User)
- 6.5.3.3.4 Rest-of-Middle East and Africa
- 6.5.3.3.4.1 Rest-of-Middle East and Africa Cell and Gene Therapy Biomanufacturing Market (by Product Type)
- 6.5.3.3.4.2 Rest-of-Middle East and Africa Cell and Gene Therapy Biomanufacturing Market (by End User)
7 Markets - Competitive Benchmarking and Company Profiles
- 7.1 Competitive Benchmarking
- 7.1.1 Competitive Landscape
- 7.1.1.1 Segmental Growth Share Matrix
- 7.1.1.1.1 Growth Share Analysis (by Product Type)
- 7.1.1.1.2 Growth Share Analysis (by Application)
- 7.1.1.2 Competitive Index (Unmet Needs and Innovations)
- 7.1.1.3 Company Position Analysis
- 7.1.1.4 Key Strategies and Developments
- 7.1.1.4.1 Funding Activities
- 7.1.1.4.2 New Offerings
- 7.1.1.4.3 Mergers and Acquisitions
- 7.1.1.4.4 Partnerships, Alliances, and Business Expansions
- 7.1.1.4.5 Key Development Analysis
- 7.2 Company Share Analysis
- 7.3 Company Profiles
- 7.3.1 Becton, Dickinson and Company
- 7.3.1.1 Company Overview
- 7.3.1.2 Role of Becton, Dickinson and Company in the Global Cell and Gene Therapy Biomanufacturing Market
- 7.3.1.3 Major Product: Key Specifications
- 7.3.1.4 Customers and Competitions/Opportunities
- 7.3.1.4.1 Key Customers
- 7.3.1.4.2 Key Competitors
- 7.3.1.5 Analyst Perspective
- 7.3.2 Bio-Rad Laboratories, Inc.
- 7.3.2.1 Company Overview
- 7.3.2.2 Role of Bio-Rad Laboratories, Inc. in the Global Cell and Gene Therapy Biomanufacturing Market
- 7.3.2.3 Major Product: Key Specifications
- 7.3.2.4 Customers and Competitions/Opportunities
- 7.3.2.4.1 Key Customers
- 7.3.2.4.2 Key Competitors
- 7.3.2.5 Analyst Perspective
- 7.3.3 Bio-Techne Corporation
- 7.3.3.1 Company Overview
- 7.3.3.2 Role of Bio-Techne Corporation in the Global Cell and Gene Therapy Biomanufacturing Market
- 7.3.3.3 Major Product: Key Specifications
- 7.3.3.4 Customers and Competitions/Opportunities
- 7.3.3.4.1 Key Competitors
- 7.3.3.5 Analyst Perspective
- 7.3.4 Danaher Corporation
- 7.3.4.1 Company Overview
- 7.3.4.2 Role of Danaher Corporation in the Global Cell and Gene Therapy Biomanufacturing Market
- 7.3.4.3 Major Product: Key Specifications
- 7.3.4.4 Customers and Competitions/Opportunities
- 7.3.4.4.1 Key Competitors
- 7.3.4.5 Analyst Perspective
- 7.3.5 Endress+Hauser Group Services AG (Analytik Jena GmbH)
- 7.3.5.1 Company Overview
- 7.3.5.2 Role of Endress+Hauser Group Services AG (Analytik Jena GmbH) in the Global Cell and Gene Therapy Biomanufacturing Market
- 7.3.5.3 Major Product: Key Specifications
- 7.3.5.4 Customers and Competitions/Opportunities
- 7.3.5.4.1 Key Customers
- 7.3.5.4.2 Key Competitors
- 7.3.5.5 Analyst Perspective
- 7.3.6 General Electric Company (GE Healthcare)
- 7.3.6.1 Company Overview
- 7.3.6.2 Role of General Electric (GE HealthCare) in the Global Cell and Gene Therapy Biomanufacturing Market
- 7.3.6.3 Major Product: Key Specifications
- 7.3.6.4 Customers and Competitions/Opportunities
- 7.3.6.4.1 Key Competitors
- 7.3.6.5 Analyst Perspective
- 7.3.7 Getinge AB
- 7.3.7.1 Company Overview
- 7.3.7.2 Role of Getinge AB in the Global Cell and Gene Therapy Biomanufacturing Market
- 7.3.7.3 Major Product: Key Specifications
- 7.3.7.4 Customers and Competitions/Opportunities
- 7.3.7.4.1 Key Competitors
- 7.3.7.5 Analyst Perspective
- 7.3.8 Infors AG
- 7.3.8.1 Company Overview
- 7.3.8.2 Role of Infors AG in the Global Cell and Gene Therapy Biomanufacturing Market
- 7.3.8.3 Major Product: Key Specifications
- 7.3.8.4 Customers and Competitions/Opportunities
- 7.3.8.4.1 Key Competitors
- 7.3.8.5 Analyst Perspective
- 7.3.9 Lonza Group Ltd
- 7.3.9.1 Company Overview
- 7.3.9.2 Role of Lonza Group Ltd in the Global Cell and Gene Therapy Biomanufacturing Market
- 7.3.9.3 Major Product: Key Specifications
- 7.3.9.4 Customers and Competitions/Opportunities
- 7.3.9.4.1 Key Competitors
- 7.3.9.5 Analyst Perspective
- 7.3.10 Merck KGaA
- 7.3.10.1 Company Overview
- 7.3.10.2 Role of Merck KGaA in the Global Cell and Gene Therapy Biomanufacturing Market
- 7.3.10.3 Major Product: Key Specifications
- 7.3.10.4 Customers and Competitions/Opportunities
- 7.3.10.4.1 Key Competitors
- 7.3.10.5 Analyst Perspective
- 7.3.11 Miltenyi Biotec B.V. & Co. KG
- 7.3.11.1 Company Overview
- 7.3.11.2 Role of Miltenyi Biotec B.V. & Co. KG in the Global Cell and Gene Therapy Biomanufacturing Market
- 7.3.11.3 Major Product: Key Specifications
- 7.3.11.4 Customers and Competitions/Opportunities
- 7.3.11.4.1 Key Customers
- 7.3.11.4.2 Key Competitors
- 7.3.11.5 Analyst Perspective
- 7.3.12 PIERRE GUERIN
- 7.3.12.1 Company Overview
- 7.3.12.2 Role of PIERRE GUERIN in the Global Cell and Gene Therapy Biomanufacturing Market
- 7.3.12.3 Major Product: Key Specifications
- 7.3.12.4 Customers and Competitions/Opportunities
- 7.3.12.4.1 Key Competitors
- 7.3.12.5 Analyst Perspective
- 7.3.13 Sartorius AG (Sartorius Stedim Biotech S.A.)
- 7.3.13.1 Company Overview
- 7.3.13.2 Role of Sartorius AG (Sartorius Stedim Biotech S.A.) in the Global Cell and Gene Therapy Biomanufacturing Market
- 7.3.13.3 Major Product: Key Specifications
- 7.3.13.4 Customers and Competitions/Opportunities
- 7.3.13.4.1 Key Customers
- 7.3.13.4.2 Key Competitors
- 7.3.13.5 Analyst Perspective
- 7.3.14 Thermo Fisher Scientific Inc.
- 7.3.14.1 Company Overview
- 7.3.14.2 Role of Thermo Fisher Scientific Inc. in the Global Cell and Gene Therapy Biomanufacturing Market
- 7.3.14.3 Major Product: Key Specifications
- 7.3.14.4 Customers and Competitions/Opportunities
- 7.3.14.4.1 Key Competitors
- 7.3.14.5 Analyst Perspective
- 7.3.15 WuXi AppTec
- 7.3.15.1 Company Overview
- 7.3.15.2 Role of WuXi AppTec in the Global Cell and Gene Therapy Biomanufacturing Market
- 7.3.15.3 Major Product: Key Specifications
- 7.3.15.4 Customers and Competitions/Opportunities
- 7.3.15.4.1 Key Competitors
- 7.3.15.5 Analyst Perspective
- 7.4 Emerging Companies
- 7.4.1 elevatebio
- 7.4.2 Adva Biotechnology
- 7.4.3 Vineti